Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01039-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Aaron F Carlin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Prodrugs, Antiviral Agents, SARS-CoV-2, Adenosine Monophosphate. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Burroughs Wellcome Fund (BWF), UC | UCSD | Center for AIDS Research, University of California, San Diego (CFAR).
Abstract (Originalsprache)
Oral broad-spectrum antivirals are urgently needed for the treatment of many emerging and contemporary RNA viruses. We previously synthesized 1- O -octadecyl-2- O -benzyl- sn -glyceryl-P-RVn (ODBG-P-RVn, V2043), a phospholipid prodrug of GS-441524 (remdesivir nucleoside, RVn), and demonstrated its in vivo efficacy in a SARS-CoV-2 mouse model. Structure-activity relationship studies focusing on the prodrug scaffold identified two modifications, 3-fluoro-4-methoxy-benzyl (V2053) and 4-cyano-benzyl (V2067), that significantly enhanced the in vitro broad-spectrum antiviral activity against multiple RNA viruses when compared to V2043. Here, we demonstrate that V2043, V2053, and V2067 are all orally bioavailable, well-tolerated, and achieve high sustained plasma levels after single oral daily dosing. All three phospholipid prodrugs are significantly more active than RVn in vitro and significantly reduce SARS-CoV-2 lung titers in prophylaxis and treatment mouse models of SARS-CoV-2 B.1.351 infection. On a molar basis, V2043 and V2067 are substantially more active than obeldesivir/GS-5245 and molnupiravir in vivo . Together, these data support the continued development of phospholipid RVn prodrugs for the treatment of SARS-CoV-2 and other RNA viruses of clinical concern.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of California San Diego, La Jolla, California, USA.
- Department of Medicine, University of California San Diego, La Jolla, California, USA.
- Department of Microbiology and Immunology, The University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Center for Pathogen Research, The University of Maryland School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Aaron F Carlin, Matthew B Frieman, Karl Y Hostetler
Förderung
- NIAID NIH HHS
- Burroughs Wellcome Fund (BWF)
- UC | UCSD | Center for AIDS Research, University of California, San Diego (CFAR)
- HHS | NIH | National Institute of Allergy and Infectious Diseases
- Bill and Melinda Gates Foundation
Zitieren
APA
Carlin, A. F., Beadle, J. R., Ardanuy, J., Clark, A. E., Rhodes, V., Garretson, A. F., Murphy, J. A., Valiaeva, N., Schooley, R. T., Frieman, M. B., & Hostetler, K. Y. (2024). Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01039-24
Vancouver
Carlin AF, Beadle JR, Ardanuy J, Clark AE, Rhodes V, Garretson AF, et al. Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01039-24
BibTeX
@article{Carlin2024,
author = {Carlin, Aaron F and Beadle, James R and Ardanuy, Jeremy and Clark, Alex E and Rhodes, Victoria and Garretson, Aaron F and Murphy, Joyce A and Valiaeva, Nadejda and Schooley, Robert T and Frieman, Matthew B and Hostetler, Karl Y},
title = {Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01039-24}
}
EUVIMED